Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group

Abstract The management of patients with glioma usually requires multimodality treatment including surgery, radiotherapy, and systemic therapy. Accurate neuroimaging plays a central role for radiotherapy planning and follow-up after radiotherapy completion. In order to maximize the radiation dose to...

Full description

Saved in:
Bibliographic Details
Published in:Neuro-oncology (Charlottesville, Va.) Vol. 23; no. 6; pp. 881 - 893
Main Authors: Galldiks, Norbert, Niyazi, Maximilian, Grosu, Anca L, Kocher, Martin, Langen, Karl-Josef, Law, Ian, Minniti, Giuseppe, Kim, Michelle M, Tsien, Christina, Dhermain, Frederic, Soffietti, Riccardo, Mehta, Minesh P, Weller, Michael, Tonn, Jörg-Christian
Format: Journal Article
Language:English
Published: US Oxford University Press 01-06-2021
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The management of patients with glioma usually requires multimodality treatment including surgery, radiotherapy, and systemic therapy. Accurate neuroimaging plays a central role for radiotherapy planning and follow-up after radiotherapy completion. In order to maximize the radiation dose to the tumor and to minimize toxic effects on the surrounding brain parenchyma, reliable identification of tumor extent and target volume delineation is crucial. The use of positron emission tomography (PET) for radiotherapy planning and monitoring in gliomas has gained considerable interest over the last several years, but Class I data are not yet available. Furthermore, PET has been used after radiotherapy for response assessment and to distinguish tumor progression from pseudoprogression or radiation necrosis. Here, the Response Assessment in Neuro-Oncology (RANO) working group provides a summary of the literature and recommendations for the use of PET imaging for radiotherapy of patients with glioma based on published studies, constituting levels 1-3 evidence according to the Oxford Centre for Evidence-based Medicine.
ISSN:1522-8517
1523-5866
DOI:10.1093/neuonc/noab013